Partner

Sejeong SON

Primary Industry Experience :
  • Pharmaceutical / Medical Devices / Healthcare
  • Biotechnology / Life Sciences
  • Specialized
    Practice Areas :
    Patent Prosecution, Litigation and Enforcement Activities, Counseling and Legal Opinions, IP / Tech Evaluation

    Biography

    Sejeong Son is a partner in the firm’s Chemical/Pharmaceutical/Life Sciences Group and leads the Group’s Japan Practice Division.

    While her practice focuses on bringing a multi-jurisdictional approach to resolve the IP issues of the firm’s Japanese pharmaceutical and biotech clients, she also provides her expertise to clients in other jurisdictions. In particular, Ms. Son is relied upon for her skillful management of enforcement activities, including litigation and trials, as well as client counseling, patent valuation, patent prosecution, and expertise in the Drug Approval-Patent Linkage system.

    Ms. Son gained fluency in the language, culture, and IP system of Japan through the firm’s overseas education program and subsequently earned her LL.M. degree at the University of Southern California. She is a licensed pharmacist.

    Profile

    • Bar Admissions
      • ·Korean Patent Bar (2004)
      • · Licensed Pharmacist (2004)
    • Education
      • ·University of Southern Califonia, School of Law (2013, LL.M.)
      • · Seoul National University, College of Pharmacy (B.Phar., 2003)
    • Experience
      • ·FirstLaw P.C. (2004~present)
    • Professional Activities
      • ·Korea Patent Attorneys Association (KPAA)
      • · Asian Patent Attorneys Association (APAA)
    • Languages
      • ·Korean, English and Japanese

    INSIGHT

    FirstLaw Newsletter

    PATENT ACT AMENDED TO LIMIT PATENT TERM EXTENSION IN KOREA

    March 31, 2025.

    News and Events

    FirstLaw P.C. wins ‘South Korea Patent Prosecution Firm of the Year’ at Global IP Awards 2024

    October 21, 2024.

    FirstLaw Newsletter

    FOREIGN CLINICAL TRIAL PERIOD RULED ELIGIBLE FOR PATENT TERM EXTENSION

    December 29, 2023.

    FirstLaw Newsletter

    PATENTABILITY OF MEDICINAL USE INVENTION OVER PUBLISHED CLINICAL TRIAL PROTOCOL UPHELD

    June 30, 2020.